^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD19.CAR-T
i
Other names: CD19.CAR-T, piggyBac transposon mediated CD19 chimeric antigen receptor gene modified T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nagoya University Graduate School of Medicine
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
11d
Protocol to measure human IL-6 secretion from CAR T cell-primed macrophage and monocyte lineage cells in vitro and in vivo using humanized mice. (PubMed, STAR Protoc)
Here, we describe a protocol to generate anti-CD19 CAR T cells and quantify human monocyte-derived IL-6 cocultured with CAR T cells and target tumor cells in vitro. We further describe a protocol to generate a humanized mouse model and evaluate CAR T cell-associated plasma IL-6 levels in vivo. For complete details on the use and execution of this protocol, please refer to Yoshikawa et al.1.
Preclinical • Journal • CAR T-Cell Therapy
|
IL6 (Interleukin 6)
|
CD19.CAR-T
3years
A Phase I Study of CD19 Chimeric Antigen Receptor-T Cells Generated By the PiggyBac Transposon Vector for Acute Lymphoblastic Leukemia (ASH 2021)
All patients receive 25mg/m 2 /d of fludarabine and 250mg/m 2 /d of cyclophosphamide for 3 days followed by a single infusion of CAR-T cells. CD19.CAR-T cell infusion produced by the piggyBac transposon gene engineering system was safe in cohort 1 of our study. As no patients had DLT in cohort 1, we are enrolling the patients in further cohorts.
P1 data • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD28 (CD28 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7)
|
CD19 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • CD19.CAR-T
Share via
